What does Glyconics do?

Introduction

This podcast is brought to you by Deep Capital LLP, authorized and regulated by the Financial Conduct Authority. Please note that investments discussed are both illiquid and high-risk and won't be suitable for all investors. They should be considered as part of a diversified portfolio. The content of this podcast should not be construed as financial or taxation advice. We recommend investors seek appropriate professional financial advice. Any views expressed may no longer be current and may have already been acted upon.

Hi, I'm Fuchsia Curry, Commercial Director, and I'm Olivia Jen, Marketing Director at Deepbridge Capital. We're delighted to be joined by Cam Punni of Glyconics, part of the Deepbridge E Life Science Fund. Hi Cam, welcome to the Deepbridge Discovery podcast.

Glyconics' Journey and Foundational Technology

Glyconics was a spin-off from a university, initiated by Dr. Bern Clark. The company focuses on the use of infrared spectroscopy as a way to analyze biomarker signatures. Initially, their technology was applied to COPD respiratory illness, and subsequently diabetes, due to the impact of COVID-19. The process involves shining infrared light into samples to detect biomarker signatures, serving as a non-invasive method for various applications, including a concentration on a point of care device for diabetes screening.

Simplifying the Technology

In simple terms, infrared light is used to scan a sample, producing a "squiggly line" or spectral pattern. By comparing these lines, one can detect the presence or absence of a condition. For diabetes, Glyconics looks at the glycation of keratin in fingernails, making it a non-invasive, sustainable alternative to blood tests.

Commercialization and Market Potential

The Glyconics device has already garnered positive feedback at conferences, showing efficiency even in imperfect conditions. The company aims to attain CE marking by the end of this year. Their primary focus areas are Finland, the UK, and Spain, with a global market potential driven by the need for early diabetes detection.

Funding and Next Steps

Glyconics sought Enterprise Investment Scheme (EIS) funding to bridge the gap between initial research and full-scale commercialization.

Regulatory and Governmental Considerations

Cam emphasized the importance of quality management systems and acknowledged the time-consuming nature of developing medical-grade software. He also noted the need for targeted grants and regulatory support to ease the pathway from R&D to market-ready products.

Reflection and Future

Cam advised other startups to start software development early and to be prepared for the rigorous documentation required. He also highlighted the value of having experienced advisors and a good governance framework.

Personal Insights

Cam concluded by sharing his admiration for individuals who provide honest and constructive feedback, such as Nelson Mandela for his compassion and patience.

Keywords

• Glyconics
• Infrared Spectroscopy
• Non-invasive
• Diabetes Screening
• CE Marking
• EIS Funding
• Medical-grade Software
• Early Detection
• Quality Management System

FAQ

What does Glyconics do?

Glyconics specializes in the use of infrared spectroscopy for non-invasive medical diagnostics, focusing primarily on diabetes and respiratory illnesses.

How does the Glyconics device work?

The device shines infrared light into a biological sample and generates a spectral pattern. This pattern is then analyzed to determine the presence or risk of certain medical conditions.

When will the Glyconics device be available commercially?

The company aims to obtain CE marking by the end of this year, which will allow them to start commercializing the device.

Why did Glyconics seek EIS funding?

EIS funding was sought to bridge the gap between initial research and full-scale commercialization, allowing the company to accelerate its development process.

What advice did Cam Punni give to other startups?

Cam emphasized the importance of starting software development early and being prepared for the rigorous documentation required for medical-grade products. He also highlighted the value of quality management systems and experienced advisors.